These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 23916815)
1. The V1/V2 loop of HIV-1 gp120 is necessary for Tat binding and consequent modulation of virus entry. Cardaci S; Soster M; Bussolino F; Marchiò S FEBS Lett; 2013 Sep; 587(18):2943-51. PubMed ID: 23916815 [TBL] [Abstract][Full Text] [Related]
2. Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus type 1 Tat and gp120 proteins. Bugatti A; Urbinati C; Ravelli C; De Clercq E; Liekens S; Rusnati M Antimicrob Agents Chemother; 2007 Jul; 51(7):2337-45. PubMed ID: 17452490 [TBL] [Abstract][Full Text] [Related]
3. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention. Auwerx J; François KO; Covens K; Van Laethem K; Balzarini J Virology; 2008 Dec; 382(1):10-9. PubMed ID: 18930512 [TBL] [Abstract][Full Text] [Related]
4. Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor. Labrosse B; Treboute C; Brelot A; Alizon M J Virol; 2001 Jun; 75(12):5457-64. PubMed ID: 11356952 [TBL] [Abstract][Full Text] [Related]
5. Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein. Marchiò S; Alfano M; Primo L; Gramaglia D; Butini L; Gennero L; De Vivo E; Arap W; Giacca M; Pasqualini R; Bussolino F Blood; 2005 Apr; 105(7):2802-11. PubMed ID: 15591114 [TBL] [Abstract][Full Text] [Related]
6. A broad spectrum anti-HIV inhibitor significantly disturbs V1/V2 domain rearrangements of HIV-1 gp120 and inhibits virus entry. Berinyuy E; Soliman ME J Recept Signal Transduct Res; 2016; 36(2):119-29. PubMed ID: 26446906 [TBL] [Abstract][Full Text] [Related]
7. Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association. Maerz AL; Drummer HE; Wilson KA; Poumbourios P J Virol; 2001 Jul; 75(14):6635-44. PubMed ID: 11413331 [TBL] [Abstract][Full Text] [Related]
8. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic. Zhang W; Canziani G; Plugariu C; Wyatt R; Sodroski J; Sweet R; Kwong P; Hendrickson W; Chaiken I Biochemistry; 1999 Jul; 38(29):9405-16. PubMed ID: 10413516 [TBL] [Abstract][Full Text] [Related]
9. Is the V3 loop involved in HIV binding to CD4? Dettin M; Ferranti P; Scarinci C; Picariello G; Di Bello C Biochemistry; 2003 Aug; 42(30):9007-12. PubMed ID: 12885233 [TBL] [Abstract][Full Text] [Related]
10. Identification of the DC-SIGN-interactive domains on the envelope glycoprotein of HIV-1 CRF07_BC. Liao CF; Wang SF; Lin YT; Ho DD; Chen YM AIDS Res Hum Retroviruses; 2011 Aug; 27(8):831-9. PubMed ID: 21142800 [TBL] [Abstract][Full Text] [Related]
11. Minimal sequence requirements for synthetic peptides derived from the V3 loop of the human immunodeficiency virus type 1 (HIV-1) to enhance HIV-1 binding to cells and infection. Zanotto C; Calderazzo F; Dettin M; Di Bello C; Autiero M; Guardiola J; Chieco-Bianchi L; De Rossi A Virology; 1995 Feb; 206(2):807-16. PubMed ID: 7856094 [TBL] [Abstract][Full Text] [Related]
12. Normal T cell receptor-mediated signaling in T cell lines stably expressing HIV-1 envelope glycoproteins. Tani Y; Tian H; Lane HC; Cohen DI J Immunol; 1993 Dec; 151(12):7337-48. PubMed ID: 7903106 [TBL] [Abstract][Full Text] [Related]
13. Binding of HIV-1 gp120 glycoprotein to silica nanoparticles modified with CD4 glycoprotein and CD4 peptide fragments. Cheng K; El-Boubbou K; Landry CC ACS Appl Mater Interfaces; 2012 Jan; 4(1):235-43. PubMed ID: 22117536 [TBL] [Abstract][Full Text] [Related]
14. Gold manno-glyconanoparticles for intervening in HIV gp120 carbohydrate-mediated processes. Di Gianvincenzo P; Chiodo F; Marradi M; Penadés S Methods Enzymol; 2012; 509():21-40. PubMed ID: 22568899 [TBL] [Abstract][Full Text] [Related]
15. Interaction of human immunodeficiency virus gp120 with the voltage-gated potassium channel BEC1. Herrmann M; Ruprecht K; Sauter M; Martinez J; van Heteren P; Glas M; Best B; Meyerhans A; Roemer K; Mueller-Lantzsch N FEBS Lett; 2010 Aug; 584(16):3513-8. PubMed ID: 20638388 [TBL] [Abstract][Full Text] [Related]
16. HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor. Bashir T; Patgaonkar M; Kumar SC; Pasi A; Reddy KV PLoS One; 2015; 10(4):e0124839. PubMed ID: 25915507 [TBL] [Abstract][Full Text] [Related]
17. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. Fouts TR; Tuskan R; Godfrey K; Reitz M; Hone D; Lewis GK; DeVico AL J Virol; 2000 Dec; 74(24):11427-36. PubMed ID: 11090138 [TBL] [Abstract][Full Text] [Related]
18. Structural basis for the interaction between focal adhesion kinase and CD4. Garron ML; Arthos J; Guichou JF; McNally J; Cicala C; Arold ST J Mol Biol; 2008 Feb; 375(5):1320-8. PubMed ID: 18078954 [TBL] [Abstract][Full Text] [Related]
19. The HIV-1 envelope glycoprotein gp120 features four heparan sulfate binding domains, including the co-receptor binding site. Crublet E; Andrieu JP; Vivès RR; Lortat-Jacob H J Biol Chem; 2008 May; 283(22):15193-200. PubMed ID: 18378683 [TBL] [Abstract][Full Text] [Related]
20. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1. Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]